The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
956
September 1, 1995
View Complete Issue         Table of Contents 2019 
A Topical Carbonic Anhydrase Inhibitor For Glaucoma
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.
A Topical Carbonic Anhydrase Inhibitor For Glaucoma
September 1, 1995 (Issue: 956)
Dorzolamide hydrochloride (Trusopt - Merck), a thienothio-pyran-2-sulfonamide carbonic anhydrase inhibitor, was recently approved by the US Food and Drug Administration in a 2% ophthalmic solution for treatment of elevated intraocular pressure in...more
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App
  • FREE online per issue CME/CE
Purchase this article:
Title: A Topical Carbonic Anhydrase Inhibitor For Glaucoma
Article code: 956b
 Electronic, downloadable article - $45


Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.